IBA announces new partnerships with Philips, Toshiba, Pravida Bau, the University of Iowa, and the Penn Department of Radiation Oncology in combination with OncoLink. These new alliances, part of the company’s growth strategy, illustrate and strengthen IBA’s focus on business development, technological innovation and educating the market.

Strategic alliance: IBA and Philips set up a strategic alliance to improve access to proton therapy solutions and enhance oncology care centers around the world. The two companies share research, technologies and solutions, and also engage in mutual marketing and representation of products for imaging and treatment in the oncology business, including an optimized integrated solution for Molecular Imaging centers. Several country-specific collaboration agreements amend the general accord for local market needs, with more to follow. Co-development will, among other developments, lead to gantry-embedded cone beam computed tomography of the highest image quality possible, and a version of Philips’ next-generation Treatment Planning System (TPS) that is fully compatible with IBA’s proton therapy systems. The agreement represents an important step toward the adaptive treatment of cancer and a personalized treatment approach, which will help to achieve the best possible result for cancer patients across the globe.
Technology and research partnerships: The University of Iowa and IBA signed a research collaboration agreement and a technology license agreement to develop ultra-high precision Intensity Modulated Proton Therapy (IMPT). The agreement includes an exclusive license for the Dynamic Collimation System (DCS), recently developed by faculty members at the University of Iowa Carver College of Medicine. Applications for the DCS could extend to many tumor sites, and it’s anticipated that it will improve hypo-fractionated treatments in proton therapy on a five-year timeline.
Infrastructure partnerships: IBA and Pravida Bau are making proton therapy easier to access with efficient turnkey solutions for the development of integrated single-room proton therapy infrastructure in Europe. Together, they will deliver a solution that will be easier and faster to install, and that will reduce the environmental footprint of projects, through the use of local material filling, rather than an over-reliance on concrete.
Commercial partnerships: IBA and the Toshiba Corporation will work together to expand access to advanced particle therapy worldwide. Toshiba Medical Systems Corporation will become the distributor in Japan for Proteus®ONE, IBA’s compact single-room proton therapy solution, and IBA will become the agent for Toshiba’s Carbon Therapy Solutions outside of Japan.
Educational partnerships: The Annual Course on Proton Therapy, organized by the Penn Department of Radiation Oncology in partnership with OncoLink and IBA, is an intensive three-day proton therapy immersion program at Penn Medicine in Philadelphia, PA. The course is designed for radiation oncology physicians, physicists and administrators who are interested in learning about proton therapy, offering in-depth insights on the practical application of proton therapy for cancer centers considering a venture into proton therapy. Read more on


Cookies policy

En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies pour vous proposer des services et des offres adaptés à vos centres d’intérêts.

Gérer vos préférences de cookies

Chez IBA, le respect de votre vie privée reste une priorité.

Les cookies fonctionnels garantissent le fonctionnement du site web. Ils ne peuvent pas être désactivés. En réglant vos préférences, vous pouvez activer et désactiver l’utilisation de ces cookies sur notre site web. Ces réglages ne seront valides que sur l’appareil que vous utilisez actuellement.

Cookies policies